The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; Medelis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
David C. Smith
Research Funding - Agensys (Inst); Aragon Pharmaceuticals (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Seagen (Inst); Tekmira (Inst); Teva (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Ryan Vance Dittamore
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Epic Sciences
 
Chan Chandhasin
Employment - ESSA
 
Frank Perabo
Employment - ESSA
Leadership - ESSA
Stock and Other Ownership Interests - ESSA
 
Robert B. Montgomery
No Relationships to Disclose